Cat. No.: HY-N0737AG

Harmine (GMP)

Name: Harmine (GMP)
Brand: MedChemExpress
SKU: HY-N0737AG
Price: 1290.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: Telepathine (GMP))

Avis client

Based on 1 Customer Validation

Harmine (GMP) (Telepathine (GMP)) is Harmine (HY-N0737A) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT_2A serotonin receptor, with an K_i of 397 nM.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No.: 442-51-3
Formule: C₁₃H₁₂N₂O
Masse moléculaire:212.25

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Harmine (GMP) Chemical Structure

CAS No.: 442-51-3

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform DYRK :

Voir tous les produits spécifiques à Isoform 5-HT Receptor :

Cellular Effect

Cell Line	Type	Value	Description	References
1A9	ED₅₀	1.6 μg/mL Compound: 3	In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line	[PMID: 10612592]
769-P	IC₅₀	48.9 μM Compound: 7	Cytotoxicity against human renal carcinoma 769-P cells assessed as reduction in optical density by MTT assay Cytotoxicity against human renal carcinoma 769-P cells assessed as reduction in optical density by MTT assay	[PMID: 23279863]
A-375	IC₅₀	72.5 μM Compound: 7	Cytotoxicity against human malignant melanoma A375 cells assessed as reduction in optical density by MTT assay Cytotoxicity against human malignant melanoma A375 cells assessed as reduction in optical density by MTT assay	[PMID: 23279863]
A549	ED₅₀	2.4 μg/mL Compound: 3	In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line	[PMID: 10612592]
A549	IC₅₀	>20 μM Compound: Harmine	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 37875056]
A549	IC₅₀	17.12 μM Compound: Harmine	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34425477]
A549	IC₅₀	17.3 μM Compound: Cpd I	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
A549	IC₅₀	42.25 μM Compound: Harmine	Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 27397495]
A549	IC₅₀	5.23 μM Compound: HM	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
A549	IC₅₀	5.89 μM Compound: Harmine	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31227365]
A549	IC₅₀	52.56 μM Compound: 6; Harmine	Antiproliferative activity against human A549 cells after 24 hrs by MTT assay Antiproliferative activity against human A549 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
A549	IC₅₀	7.76 μM Compound: Har	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 29129513]
Bel-7402	IC₅₀	54 μM Compound: 1	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 23291116]
Bel-7402	IC₅₀	54 μM Compound: Harmine	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 18462839]
BGC-823	IC₅₀	15.63 μM Compound: HM	Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
BGC-823	IC₅₀	63.2 μM Compound: 7	Cytotoxicity against human gastric carcinoma BGC823 cells assessed as reduction in optical density by MTT assay Cytotoxicity against human gastric carcinoma BGC823 cells assessed as reduction in optical density by MTT assay	[PMID: 23279863]
BGC-823	IC₅₀	68 μM Compound: 1	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 23291116]
BGC-823	IC₅₀	68 μM Compound: Harmine	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 18462839]
CAKI-1	ED₅₀	1.9 μg/mL Compound: 3	In vitro cytotoxic activity was determined against renal cancer (CAKI-1) cell line In vitro cytotoxic activity was determined against renal cancer (CAKI-1) cell line	[PMID: 10612592]
COLO 205	IC₅₀	26 μM Compound: Harmine	Antiproliferative activity against human COLO205 cells after 24 hrs by MTT assay Antiproliferative activity against human COLO205 cells after 24 hrs by MTT assay	[PMID: 22365759]
COLO 205	IC₅₀	46 μM Compound: Harmine	Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay	[PMID: 22202437]
COLO 205	IC₅₀	8 μM Compound: Harmine	Antiproliferative activity against human COLO205 cells by MTT assay Antiproliferative activity against human COLO205 cells by MTT assay	[PMID: 22749421]
COLO 205	IC₅₀	8 μM Compound: Harmine	Cytotoxicity against human COLO205 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 28216402]
DU-145	IC₅₀	12.02 μM Compound: Har	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 29129513]
DU-145	IC₅₀	9.63 μM Compound: Harmine	Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31227365]
FM3A	EC₅₀	1.8 x 10^-5M Compound: 1i, harmine	In vitro cytotoxic activity tested in mouse mammary tumor FM3A cells In vitro cytotoxic activity tested in mouse mammary tumor FM3A cells	[PMID: 15026051]
H9	EC₅₀	0.52 μM Compound: 9	Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication	[PMID: 11473435]
H9	IC₅₀	26.4 μM Compound: 9	Cytotoxicity against human H9 cells Cytotoxicity against human H9 cells	[PMID: 11473435]
HCT-116	IC₅₀	>20 μM Compound: Harmine	Antiproliferative activity against human HCT-116 cells Antiproliferative activity against human HCT-116 cells	[PMID: 37875056]
HCT-116	IC₅₀	43.8 μM Compound: Harmine	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
HCT-116	IC₅₀	43.8 μM Compound: Harmine	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 35272009]
HCT-116	IC₅₀	46.7 μM Compound: Harmine	Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26555243]
HCT-116	IC₅₀	46.7 μM Compound: Harmine	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29288941]
HCT-116	IC₅₀	46.7 μM Compound: Harmine	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 30108831]
HCT-116	IC₅₀	6.94 μM Compound: HM	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
HCT-116	IC₅₀	7.64 μM Compound: HAR	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38677112]
HEK293	IC₅₀	0.4 μM Compound: Hrm	Inhibition of tetracycline-inducible EGFP-DYRK1A (unknown origin) expressed in HEK293 cells coexpressing full length human EGFP-tau protein assessed as reduction in tau-Thr212 phosphorylation incubated overnight by immunofluorescence assay Inhibition of tetracycline-inducible EGFP-DYRK1A (unknown origin) expressed in HEK293 cells coexpressing full length human EGFP-tau protein assessed as reduction in tau-Thr212 phosphorylation incubated overnight by immunofluorescence assay	[PMID: 26896709]
HEK-293T	IC₅₀	20.98 μM Compound: HAR	Antiproliferative activity against human HEK293T cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HEK293T cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38677112]
HEL	ED₅₀	1.9 μg/mL Compound: 3	In vitro cytotoxic activity was determined against embryonic lung fibroblast (HEL) cell line In vitro cytotoxic activity was determined against embryonic lung fibroblast (HEL) cell line	[PMID: 10612592]
HeLa	IC₅₀	>10 μM Compound: Harmine	Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis	[PMID: 26555243]
HeLa	IC₅₀	>10 μM Compound: Harmine	Inhibition of HDAC in human HeLa nuclear extract Inhibition of HDAC in human HeLa nuclear extract	[PMID: 30245394]
HeLa	IC₅₀	16.21 μM Compound: Har	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29129513]
HeLa	IC₅₀	60 μM Compound: 1	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 23291116]
HeLa	IC₅₀	60 μM Compound: Harmine	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 18462839]
HeLa	IC₅₀	8 μM Compound: Harmine	Cytotoxicity against human HeLa cells after 5 days by MTT assay Cytotoxicity against human HeLa cells after 5 days by MTT assay	[PMID: 30193214]
HeLa	IC₅₀	85.28 μM Compound: 6; Harmine	Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay	10.1039/C5MD00581G
HeLa	IC₅₀	9.66 μM Compound: Harmine	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31227365]
HepG2	IC₅₀	>20 μM Compound: Harmine	Antiproliferative activity against human HepG2 cells Antiproliferative activity against human HepG2 cells	[PMID: 37875056]
HepG2	IC₅₀	>250 μM Compound: HAR	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay	[PMID: 34274829]
HepG2	IC₅₀	>250 μM Compound: HAR	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay	[PMID: 35551033]
HepG2	IC₅₀	>250 μM Compound: HAR	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37696205]
HepG2	IC₅₀	>250 μM Compound: Harmine	Cytotoxicity against human HepG2 cells measured after 24 hrs by neutral red assay Cytotoxicity against human HepG2 cells measured after 24 hrs by neutral red assay	[PMID: 31812035]
HepG2	IC₅₀	14.93 μM Compound: HAR	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38677112]
HepG2	IC₅₀	16.8 μM Compound: HM	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
HepG2	IC₅₀	19.23 μM Compound: Cpd I	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
HepG2	IC₅₀	46 μM Compound: 1	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 23291116]
HepG2	IC₅₀	46 μM Compound: Harmine	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 18462839]
HepG2	IC₅₀	49.96 μM Compound: Harmine	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 32787089]
HepG2	IC₅₀	51.2 μM Compound: Harmine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29288941]
HepG2	IC₅₀	51.2 μM Compound: Harmine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30108831]
HepG2	IC₅₀	53.6 μM Compound: Harmine	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
HepG2	IC₅₀	53.6 μM Compound: Harmine	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 31120744]
HGC-27	IC₅₀	3.52 μM Compound: Harmine	Antiproliferative activity against human HGC27 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HGC27 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HL-60	IC₅₀	62.45 μM Compound: 6; Harmine	Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
HL-60	IC₅₀	7.55 μM Compound: 11	Antiproliferative activity against human HL60 cells by tryphan blue assay Antiproliferative activity against human HL60 cells by tryphan blue assay	[PMID: 28128938]
Hs 683	IC₅₀	37 μM Compound: 1	Growth inhibition of human Hs 683 cells after 3 days by MTT assay Growth inhibition of human Hs 683 cells after 3 days by MTT assay	[PMID: 22770529]
Hs 683	IC₅₀	37 μM Compound: 1, Harmine	Cytostatic activity against human Hs683 cells after 72 hrs by videomicroscopy Cytostatic activity against human Hs683 cells after 72 hrs by videomicroscopy	[PMID: 25747498]
HT-22	IC₅₀	56.5 μM Compound: 14	Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 36876904]
HT-29	IC₅₀	>20 μM Compound: Harmine	Antiproliferative activity against human HT-29 cells Antiproliferative activity against human HT-29 cells	[PMID: 37875056]
HT-29	IC₅₀	12.15 μM Compound: Cpd I	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
HT-29	IC₅₀	3.52 μM Compound: Harmine	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HT-29	IC₅₀	41.8 μM Compound: Harmine	Antiproliferative activity against human HT-29 cells by MTT assay Antiproliferative activity against human HT-29 cells by MTT assay	[PMID: 32787089]
IMR-32	IC₅₀	38 μM Compound: Harmine	Antiproliferative activity against human IMR32 cells after 24 hrs by MTT assay Antiproliferative activity against human IMR32 cells after 24 hrs by MTT assay	[PMID: 22365759]
IMR-32	IC₅₀	68 μM Compound: Harmine	Cytotoxicity against human IMR32 cells after 24 hrs by MTT assay Cytotoxicity against human IMR32 cells after 24 hrs by MTT assay	[PMID: 22202437]
K562	IC₅₀	14 μM Compound: Harmine	Antiproliferative activity against human K562 cells by MTT assay Antiproliferative activity against human K562 cells by MTT assay	[PMID: 22749421]
K562	IC₅₀	14 μM Compound: Harmine	Cytotoxicity against human K562 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human K562 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 28216402]
K562	IC₅₀	32 μM Compound: Harmine	Antiproliferative activity against human K562 cells after 24 hrs by MTT assay Antiproliferative activity against human K562 cells after 24 hrs by MTT assay	[PMID: 22365759]
K562	IC₅₀	45 μM Compound: Harmine	Cytotoxicity against human K562 cells after 24 hrs by MTT assay Cytotoxicity against human K562 cells after 24 hrs by MTT assay	[PMID: 22202437]
K562	IC₅₀	45 μM Compound: Harmine	Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 22516283]
KB	ED₅₀	2.2 μg/mL Compound: 3	In vitro cytotoxic activity was determined against epidermoid carcinoma of the nasopharynx (KB) cell line In vitro cytotoxic activity was determined against epidermoid carcinoma of the nasopharynx (KB) cell line	[PMID: 10612592]
KB	ED₅₀	2.5 μg/mL Compound: 3	In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-VIN (expressing P-glycoprotein) In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-VIN (expressing P-glycoprotein)	[PMID: 10612592]
KB	ED₅₀	3.7 μg/mL Compound: 3	In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-7d (pleotrophic resistance including MRP multidrug resistant protein) In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-7d (pleotrophic resistance including MRP multidrug resistant protein)	[PMID: 10612592]
KB	ED₅₀	4.3 μg/mL Compound: 3	In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-CPT (pleotrophic mechanism including level of topoisomerase I) In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-CPT (pleotrophic mechanism including level of topoisomerase I)	[PMID: 10612592]
KB	IC₅₀	57.8 μM Compound: 7	Cytotoxicity against human epidermoid carcinoma of the nasopharynx KB cells assessed as reduction in optical density by MTT assay Cytotoxicity against human epidermoid carcinoma of the nasopharynx KB cells assessed as reduction in optical density by MTT assay	[PMID: 23279863]
L02	IC₅₀	25.09 μM Compound: HM	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
L02	IC₅₀	9.49 μM Compound: Cpd I	Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
LoVo	IC₅₀	53.2 μM Compound: Harmine	Antiproliferative activity against human LoVo cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human LoVo cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26555243]
LoVo	IC₅₀	53.2 μM Compound: Harmine	Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay	[PMID: 30108831]
MCF7	ED₅₀	10.5 μg/mL Compound: 3	In vitro cytotoxic activity against MCF-7 (human breast cancer) cell line. In vitro cytotoxic activity against MCF-7 (human breast cancer) cell line.	[PMID: 10612592]
MCF7	IC₅₀	10.78 μM Compound: Har	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29129513]
MCF7	IC₅₀	13.37 μM Compound: Cpd I	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
MCF7	IC₅₀	13.5 μM Compound: HAR	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38677112]
MCF7	IC₅₀	15.27 μM Compound: HM	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
MCF7	IC₅₀	16.94 μM Compound: Harmine	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 33744443]
MCF7	IC₅₀	3.52 μM Compound: Harmine	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31546197]
MCF7	IC₅₀	68.33 μM Compound: Harmine	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 27397495]
MCF7	IC₅₀	70.7 μM Compound: 6; Harmine	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
MCF7	IC₅₀	72 μM Compound: Harmine	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 18462839]
MDA-MB-231	IC₅₀	13.21 μM Compound: Cpd I	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
MDA-MB-231	IC₅₀	21.91 μM Compound: Harmine	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 33744443]
MDA-MB-231	IC₅₀	32 μM Compound: Harmine	Antiproliferative activity against human MDA-MB-231 cells by MTT assay Antiproliferative activity against human MDA-MB-231 cells by MTT assay	[PMID: 22749421]
MDA-MB-231	IC₅₀	32 μM Compound: Harmine	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 28216402]
MDA-MB-231	IC₅₀	54 μM Compound: Harmine	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 22202437]
MDA-MB-231	IC₅₀	54 μM Compound: Harmine	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 22516283]
MDA-MB-435	IC₅₀	>100 μM Compound: Harmine	Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 1 day by MTT assay Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 1 day by MTT assay	[PMID: 33813152]
MDA-MB-435	IC₅₀	17.1 μM Compound: Harmine	Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 5 days by MTT assay Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 5 days by MTT assay	[PMID: 33813152]
MDCK-II	GI₅₀	2.3 μM Compound: Harmine	Cytotoxicity against wild-type MDCK2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against wild-type MDCK2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27280693]
MDCK-II	GI₅₀	2.42 μM Compound: Harmine	Cytotoxicity against MDCK2 cells expressing human ABCG2 assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against MDCK2 cells expressing human ABCG2 assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27280693]
NCI-H2228	IC₅₀	31.06 μM Compound: Harmine	Antiproliferative activity against human EML4-ALK positive H2228 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human EML4-ALK positive H2228 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34425477]
OE33	IC₅₀	18 μM Compound: 1	Growth inhibition of human OE33 cells after 3 days by MTT assay Growth inhibition of human OE33 cells after 3 days by MTT assay	[PMID: 22770529]
Pancreatic beta cell	EC₅₀	7.48 μM Compound: Telepathine	Induction of cell proliferation in rat beta cells Induction of cell proliferation in rat beta cells	[PMID: 32077280]
PC-3	IC₅₀	15.57 μM Compound: Cpd I	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
PC-3	IC₅₀	3.52 μM Compound: Harmine	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
Platelet	IC₅₀	>130 μM Compound: Harmine	Antiplatelet aggregation activity against collagen-induced platelet Antiplatelet aggregation activity against collagen-induced platelet	[PMID: 20329729]
Platelet	IC₅₀	130 μM Compound: Harmine	Antiplatelet activity in rabbit platelets assessed as inhibition of collagen-induced platelet aggregation Antiplatelet activity in rabbit platelets assessed as inhibition of collagen-induced platelet aggregation	[PMID: 21983333]
SGC-7901	IC₅₀	40.82 μM Compound: Harmine	Cytotoxicity against human SGC7901 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxicity against human SGC7901 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 27397495]
SGC-7901	IC₅₀	70.36 μM Compound: 6; Harmine	Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
SK-MEL-2	ED₅₀	18.5 μg/mL Compound: 3	In vitro cytotoxic activity was determined against melanoma cancer (SK-MEL-2) cell line In vitro cytotoxic activity was determined against melanoma cancer (SK-MEL-2) cell line	[PMID: 10612592]
SK-OV-3	IC₅₀	74.6 μM Compound: 7	Cytotoxicity against human ovary adenocarcinoma SKOV3 cells assessed as reduction in optical density by MTT assay Cytotoxicity against human ovary adenocarcinoma SKOV3 cells assessed as reduction in optical density by MTT assay	[PMID: 23279863]
SMMC-7721	IC₅₀	47.6 μM Compound: Harmine	Antiproliferative activity against human SMMC7721 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
SMMC-7721	IC₅₀	47.6 μM Compound: Harmine	Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 31120744]
SMMC-7721	IC₅₀	55.3 μM Compound: Harmine	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 29288941]
SMMC-7721	IC₅₀	55.3 μM Compound: Harmine	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 30108831]
SMMC-7721	IC₅₀	59.44 μM Compound: Harmine	Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 27397495]
SW-620	IC₅₀	42.8 μM Compound: Harmine	Antiproliferative activity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26555243]
SW-620	IC₅₀	7.32 μM Compound: HAR	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38677112]
T98G	IC₅₀	24 μM Compound: 1	Growth inhibition of human T98G cells after 3 days by MTT assay Growth inhibition of human T98G cells after 3 days by MTT assay	[PMID: 22770529]
U-373MG ATCC	IC₅₀	32 μM Compound: 1	Growth inhibition of human U373 cells after 3 days by MTT assay Growth inhibition of human U373 cells after 3 days by MTT assay	[PMID: 22770529]
U-87MG ATCC	ED₅₀	14.5 μg/mL Compound: 3	In vitro cytotoxic activity against U-87-MG (glioblastoma) cell line. In vitro cytotoxic activity against U-87-MG (glioblastoma) cell line.	[PMID: 10612592]
U-87MG ATCC	IC₅₀	7.2 μM Compound: Hrm	Growth inhibition of human U87MG cells after 4 days by MTT assay Growth inhibition of human U87MG cells after 4 days by MTT assay	[PMID: 26896709]

In Vitro

Harmine (GMP) inhibits tau phosphorylation by DYRK1A by selected DANDYs, with an IC₅₀ of 190 nM^[2]. Harmine (GMP) negatively regulates homologous recombination (HR) by interfering Rad51 recruitment, resulting in severe cytotoxicity in hepatoma cells. Furthermore, NHEJ inhibitor Nu7441 markedly sensitizes Hep3B cells to the anti-proliferative effects of Harmine^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

It is shown that brain water content is significantly increased in the TBI group. Treatment with Harmine (GMP) significantly reduces the tissue water content at 1, 3 and 5 days, compared with the TBI group. Harmine (GMP) treatment significantly reduces the escape latency at 3 and 5 days, compared with the TBI group. Post-TBI administration of Harmine (GMP) significantly improves the motor function recovery of the rats at 1, 3 and 5 days following TBI, compared with the TBI group without Harmine (GMP) treatment. The neuronal survival rate in the Harmine (GMP)-treated group is significantly increased, compared with the TBI group. Administration of Harmine (GMP) results in marked elevation in the expression of GLT-1, compared with the TBI group. The administration of Harmine (GMP) significantly reduces the expression of caspase 3, compared with the TBI group^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 442-51-3
Appearance Solid
Masse moléculaire 212.25
Formule C₁₃H₁₂N₂O
Color White to off-white
SMILES

CC1=NC=CC2=C1NC3=C2C=CC(OC)=C3
Synonyms

Telepathine (GMP)
Structure Classification
- Alkaloids
- Indole Alkaloids
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (273 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Glennon RA, et al. Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. Drug Alcohol Depend. 2000 Aug 1;60(2):121-32. [Content Brief]

[2]. Neumann F, et al. DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives. Sci Rep. 2018 Feb 12;8(1):2859. [Content Brief]

[3]. Zhang L, et al. Harmine suppresses homologous recombination repair and inhibits proliferation of hepatoma cells. Cancer Biol Ther. 2015;16(11):1585-92. [Content Brief]

[4]. Zhong Z, et al. Treatment with harmine ameliorates functional impairment and neuronal death following traumatic brain injury. Mol Med Rep. 2015 Dec;12(6):7985-91. [Content Brief]

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Harmine (GMP)

Harmine

Harmine (Standard)

Harmine hydrochloride

GNF4877

GSK-626616

ID-8

AZ191

EHT 1610

Phlorizin

Harmol

Jervine

Rasagiline mesylate

Voir tous les produits spécifiques à Isoform DYRK

Voir tous les produits spécifiques à Isoform 5-HT Receptor

Activité biologique

Chemical Information

Pureté et documentation

Références

Calculators

Help & FAQs

Bioz

Harmine (GMP)

Harmine

Harmine (Standard)

Harmine hydrochloride

GNF4877

GSK-626616

ID-8

AZ191

EHT 1610

Phlorizin

Harmol

Jervine

Rasagiline mesylate

Voir tous les produits spécifiques à Isoform DYRK

Voir tous les produits spécifiques à Isoform 5-HT Receptor

Activité biologique

Chemical Information

Pureté et documentation

Références

Calculators

Help & FAQs

Harmine (GMP) Related Classifications

HY-N0737AG Related Classifications

Bioz